Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic, genotype 1, hepatitis C with detectable HCV RNA~* HIV-1 infection for \>6 months~* Documentation of a liver biopsy within 1 year before the screening visit showing evidence of hepatitis (demonstrated by inflammation and/or fibrosis)~Exclusion Criteria:~* Previous treatment with any approved or investigational drug or drug regimen for the treatment of hepatitis C~* Previous treatment with interferon or ribavirin~* Evidence of hepatic decompensation in cirrhotic subjects~* Subjects who have participated in a clinical study involving administration of an investigational drug within 2 months~* Part A only: subjects who have been on a HAART regimen within 12 weeks before study start

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Part A (Type: EXPERIMENTAL): The dose of ribavirin used (fixed versus weight-based) is region dependent
- Part B (Type: EXPERIMENTAL): The dose of ribavirin used (fixed versus weight-based) is region dependent

Based on this trial design, predict the completion outcome and termination type (if applicable).